CINECA IRIS Institutional Research Information System

GROTTOLI, Silvia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.317
EU - Europa 4.287
AS - Asia 2.743
SA - Sud America 166
OC - Oceania 31
AF - Africa 26
Continente sconosciuto - Info sul continente non disponibili 6
Totale 13.576
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.169
CN - Cina 1.445
IT - Italia 1.050
SE - Svezia 614
SG - Singapore 589
IE - Irlanda 572
UA - Ucraina 437
DE - Germania 357
FR - Francia 323
FI - Finlandia 272
KR - Corea 247
GB - Regno Unito 220
PL - Polonia 127
CA - Canada 106
JP - Giappone 106
VN - Vietnam 104
BR - Brasile 89
IN - India 56
AT - Austria 53
NL - Olanda 46
ES - Italia 45
RU - Federazione Russa 39
AR - Argentina 34
BE - Belgio 32
MX - Messico 29
UZ - Uzbekistan 29
HK - Hong Kong 26
AU - Australia 25
PH - Filippine 24
ID - Indonesia 23
CO - Colombia 22
GR - Grecia 22
TR - Turchia 22
CH - Svizzera 15
PT - Portogallo 14
IQ - Iraq 13
CL - Cile 11
CR - Costa Rica 11
MU - Mauritius 11
RO - Romania 11
IL - Israele 9
AE - Emirati Arabi Uniti 8
RS - Serbia 7
TH - Thailandia 7
IR - Iran 6
NZ - Nuova Zelanda 6
OM - Oman 6
PE - Perù 6
TW - Taiwan 6
CZ - Repubblica Ceca 5
EU - Europa 5
SA - Arabia Saudita 5
BT - Bhutan 4
DK - Danimarca 4
EG - Egitto 4
HR - Croazia 4
BY - Bielorussia 3
HU - Ungheria 3
BG - Bulgaria 2
CI - Costa d'Avorio 2
DZ - Algeria 2
LT - Lituania 2
LV - Lettonia 2
MY - Malesia 2
QA - Qatar 2
SI - Slovenia 2
TN - Tunisia 2
UY - Uruguay 2
VE - Venezuela 2
AL - Albania 1
AP - ???statistics.table.value.countryCode.AP??? 1
BH - Bahrain 1
ET - Etiopia 1
GE - Georgia 1
GT - Guatemala 1
IM - Isola di Man 1
KE - Kenya 1
LB - Libano 1
LU - Lussemburgo 1
MQ - Martinica 1
MT - Malta 1
PK - Pakistan 1
SC - Seychelles 1
UG - Uganda 1
ZA - Sudafrica 1
Totale 13.576
Salva come PNG Salva come JPEG
Città #
Beijing 1.150
Chandler 922
Dublin 562
Houston 493
Singapore 481
Santa Clara 278
Jacksonville 260
Medford 218
Nyköping 217
Torino 210
Ashburn 209
Fairfield 195
Princeton 184
Columbus 182
Ann Arbor 172
Dearborn 164
Villeurbanne 159
Wilmington 134
Milan 119
Warsaw 112
Turin 102
Woodbridge 99
Redwood City 96
Boardman 68
Cambridge 67
Dong Ket 64
Seattle 59
Verona 55
Toronto 52
Boston 50
Guangzhou 48
Vienna 48
Fremont 37
Rome 36
Lachine 34
Tokyo 34
Hangzhou 30
Brussels 29
Norwalk 28
Pisa 28
San Mateo 24
Falls Church 23
Jakarta 21
Hebei 19
Los Angeles 19
Mountain View 19
Pune 19
New York 18
Detroit 17
Nanjing 17
Seoul 17
São Paulo 17
Hefei 15
Shanghai 15
Kunming 14
Munich 14
San Diego 13
Washington 13
Chicago 12
Lappeenranta 12
Melito Di Napoli 12
Mexico 12
Barcelona 11
Central District 11
London 11
Mexico City 11
Santiago 11
Bogotá 10
Chengdu 10
Modena 10
Munro 10
Nola 10
Philadelphia 10
Istanbul 9
Buenos Aires 8
Helsinki 8
Alajuela 7
Alessandria 7
Florence 7
Hanoi 7
Nanchang 7
Padova 7
Palermo 7
Sydney 7
Tappahannock 7
Amsterdam 6
Athens 6
Jinan 6
Muscat 6
Rio De Janeiro 6
Rotterdam 6
San Giuliano Milanese 6
Treviso 6
Ankara 5
Bangalore 5
Berlin 5
Brescia 5
Changchun 5
Duncan 5
Moscow 5
Totale 8.133
Salva come PNG Salva come JPEG
Nome #
Management of GH treatment in adult GH deficiency 1.275
ACROSCORE: a new and simple tool for the diagnosis of acromegaly, a rare and underdiagnosed disease 244
Acylated ghrelin as a provocative test for the diagnosis of GH deficiency in adults. 199
USEFULNESS OF AN AD HOC QUESTIONNAIRE (ACRO-CQ) FOR THE SYSTEMATIC ASSESSMENT OF ACROMEGALY COMORBIDITIES AT DIAGNOSIS AND THEIR MANAGEMENT AT FOLLOW-UP 194
Predictors of morbidity and mortality in acromegaly: an Italian survey. 185
IDENTIFICATION OF RISK CONDITIONS FOR THE DEVELOPMENT OF ADRENAL DISORDERS: HOW OPTIMIZED PUBMED SEARCH STRATEGIES MAKES THE DIFFERENCE 182
EARLY ENDOCRINE DYSFUNCTION IN CRITICAL ILLNESS OF DIFFERENT AETIOLOGY 178
Short-term fasting abolishes the sex-related difference in GH and leptin secretion in humans. 174
Acromegaly is associated with increased cancer risk: a survey in Italy 170
Alprazolam, a benzodiazepine, does not modify the ACTH and cortisol response to hCRH and AVP, but blunts the cortisol response to ACTH in humans. 145
Activation of pituitary axis according to underlying critical illness and its effect on outcome. 136
Arginine counteracts the inhibitory effect of recombinant human insulin-like growth factor I on the somatotroph responsiveness to growth hormone-releasing hormone in humans. 127
L'ipopituitarismo post trauma cranico: dall'età pediatrica all'età adulta 120
Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects. 114
The enhancing effect of pyridostigmine on the GH response to GHRH undergoes an accelerated age-related reduction in Down syndrome. 114
Benzodiazepines and anterior pituitary function. 112
Human aging and the GH-IGF-I axis. 112
Adrenal responsiveness to high, low and very low ACTH 1-24 doses in obesity. 110
GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism. 110
Blunted GH response to growth hormone-releasing hormone (GHRH) alone or combined with arginine in non-insulin-dependent diabetes mellitus. 110
DUAL-RELEASE HYDROCORTISONE IN ADDISON’S DISEASE-A REVIEW OF THE LITERATURE 106
Testing pituitary function in aging individuals 102
The GH/IGF-I axis in obesity: influence of neuro-endocrine and metabolic factors. 100
Traumatic Brain Injury as Frequent Cause of Hypopituitarism and Growth Hormone Deficiency: Epidemiology, Diagnosis, and Treatment 100
Effects of alprazolam, a benzodiazepine, on the ACTH-, GH- and PRL-releasing activity of hexarelin, a synthetic peptidyl GH secretagogue (GHS), in patients with simple obesity and in patients with Cushing's disease. 97
Endocrine and metabolic response to extreme altitude and physical exercise in athletes. 96
Somatotrope responsiveness to Hexarelin, a synthetic hexapeptide, is refractory to the inhibitory effect of glucose in obesity. 95
Alprazolam (a benzodiazepine activating GABA receptor) reduces the neuroendocrine responses to insulin-induced hypoglycaemia in humans. 95
ACROSTUDY: the Italian experience 95
First but not second postoperative day growth hormone assessments as early predictive tests for long-term acromegaly persistence 95
Early detection of antipituitary antibodies and pituitary dysfunction in patients with severe traumatic brain injury 94
Acylated ghrelin as provocative test for the diagnosis of ACTH deficiency in patients with hypothalamus–pituitary disease 92
Metabolic modulation of the growth hormone-releasing activity of hexarelin in man. 92
Concomitant impairment of GH secretion and peripheral sensitivity in obese patients with obstructive sleep apnea syndrome 91
Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study 91
ADRENAL SENSITIVITY TO ACTH1-24 AS FUNCTION OF AGE, BODY WEIGHT AND PITUITARY FUNCTION 89
Progression of pituitary tumours: impact of GH secretory status and long-term GH replacement therapy 88
Growth hormone-releasing activity of growth hormone-releasing peptide-6 is maintained after short-term oral pretreatment with the hexapeptide in normal aging. 87
Cortistatin-17 and somatostatin-14 display the same effects on growth hormone, prolactin, and insulin secretion in patients with acromegaly or prolactinoma 87
SENSITIVITY AND SPECIFICITY OF DIFFERENT PROVOCATIVE TESTS ASSESSING THE FUNCTION OF HYPOTHALAMO-PITUITARY-ADRENAL (HPA) AXIS IN PATIENTS SUSPECTED FOR SECONDARY HYPOADRENALISM 87
Three-Dimensional Endoscopic Endonasal Approach and Outcomes in Sellar Lesions: A Single-Center Experience of 104 Cases 86
Alprazolam, a benzodiazepine, blunts but does not abolish the ACTH and cortisol response to hexarelin, a GHRP, in obese patients. 85
ADRENAL SENSITIVITY TO ACTH1-24 AS FUNCTION OF AGE, BODY WEIGHT AND PITUITARY FUNCTION 85
Short-term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging. 84
Effects of chronic slow release-lanreotide treatment on insulin-like growth factor system and metabolic parameters in acromegalic patients 84
Treatment of acromegaly with SS analogues: should GH and IGF-I target levels be lowered to assert a tight control of the disease? 84
Hypopituitaric patients with corticotropin insufficiency show marked impairment of the cortisol response to ACTH (1-24) independently of the duration of the disease. 84
Age-related endocrine and metabolic changes in simple obesity. 83
GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism. 82
[Growth hormone and lipids] 82
Maximal secretory capacity of somatotrope cells in obesity: comparison with GH deficiency. 82
Growth hormone levels in the diagnosis of growth hormone deficiency in adulthood. 82
Three-month treatment with metformin or dexfenfluramine does not modify the effects of diet on anthropometric and endocrine-metabolic parameters in abdominal obesity. 82
The effects of altitude on the hormonal response to physical exercise 81
Retrospective observational analysis of non-irradiated non-functioning pituitary adenomas 80
Assessment of GH/IGF-I axis in obesity by evaluation of IGF-I levels and the GH response to GHRH+arginine test. 79
Update on epidemiology, etiology, and diagnosis of adult growth hormone deficiency 79
Assessment of the awareness and management of sleep apnea syndrome in acromegaly. The COM.E.TA (Comorbidities Evaluation and Treatment in Acromegaly) Italian Study Group 79
Cost-of-illness study in acromegalic patients in Italy. 78
Effect of galanin on basal and stimulated secretion of prolactin, gonadotropins, thyrotropin, adrenocorticotropin and cortisol in humans. 77
Untreated adult GH deficiency is not associated with the development of metabolic risk factors: a long-term observational study 77
Growth hormone/insulin-like growth factor I axis, glucose metabolism, and lypolisis but not leptin show some degree of refractoriness to short-term fasting in acromegaly 77
Diagnosis of adult GH deficiency 75
Court dwarfs: an overview of European paintings from fifteenth to eighteenth century. 75
Insulin-like growth factor I levels and the diagnosis of adult growth hormone deficiency 75
Diagnostic reliability of a single IGF-I measurement in 237 adults with total anterior hypopituitarism and severe GH deficiency. 74
Early copeptin determination allows prompt diagnosis of post-neurosurgical central diabetes insipidus 74
Endocrinology and Art--Väinö Myllyrinne: the world's tallest acromegalic soldier on a postcard. 73
Hypopituitarism following brain injury: when does it occur and how best to test? 73
EFFECTS OF ALPRAZOLAM, A BENZODIAZEPINE, ON THE GH, ACTH, CORTISOL AND CATECHOLAMINE RESPONSES TO INSULIN-INDUCED HYPOGLYCEMIA IN HUMANS 70
Acromegaly and joint pain: is there something more? A cross-sectional study to evaluate rheumatic disorders in growth hormone secreting tumor patients 70
Comparisons among old and new provocative tests of GH secretion in 178 normal adults. 69
The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index 69
Three-hour spontaneous GH secretion profile is as reliable as oral glucose tolerance test for the diThree-hour spontaneous GH secretion profile is as reliable as oral glucose tolerance test for the diagnosis of acromegaly. 69
The inhibitory effect of glucose on growth hormone secretion is lost in obesity but not in hypertension. 68
Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing's syndrome. 68
Obstructive sleep apnea syndrome impairs insulin sensitivity independently of anthropometric variables 67
Pegvisomant in acromegaly: why, when, how. 66
Biliary adverse events in acromegaly during somatostatin receptor ligands: predictors of onset and response to ursodeoxycholic acid treatment 66
Retesting the childhood-onset GH-deficient patient 65
Galanin positively modulates prolactin secretion in normal women. 65
A New Clinical Model to Estimate the Pre-Test Probability of Cushing's Syndrome: The Cushing Score 65
Effects of glucose, free fatty acids or arginine load on the GH-releasing activity of ghrelin in humans. 64
Relationships between IGF-I and age, gender, body mass, fat distribution, metabolic and hormonal variables in obese patients. 64
Acromegalia e gravidanza: quali rischi per la madre e per il feto 64
The adrenal sensitivity to ACTH stimulation is preserved in anorexia nervosa 63
Ghrelin and anterior pituitary function 63
Functioning and non-functioning pituitary adenomas in 173 adult and elderly patients 63
Development and Internal Validation of a Predictive Model for Adult GH Deficiency Prior to Stimulation Tests 63
EFFECTS OF CORTISTATIN-17 AND SOMATOSTATIN-14 ON ACTH AND CORTISOL HYPERSECRETION IN PATIENTS WITH CUSHING’S DISEASE 62
Effects of glucose load and/or arginine on insulin and growth hormone secretion in hyperprolactinemia and obesity. 61
First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous medical Education) Study Group. 61
IGFs and IGFBPs in adult growth hormone deficiency. 61
Association of craniopharyngioma and pituitary adenoma. 61
Endocrine activities of cortistatin-14 and its interaction with GHRH and ghrelin in humans 61
Normal development of lymphokine activated killing (LAK) in peripheral blood lymphocytes from hyperprolactinemic patients. 60
Second-Day Morning Cortisol Levels after Transsphenoidal Surgery Are Accurate Predictors of Secondary Adrenal Insufficiency with Diagnostic Cut-Offs Similar to Those in Non-Stressed Conditions 60
The manifesto A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) study group one year later: what to keep and what to amend? 60
ENDOCRINE DISRUPTING CHEMICALS: EFFECTS ON PITUITARY, THYROID AND ADRENAL GLANDS 60
Hexarelin, a synthetic growth hormone releasing peptide, stimulates prolactin secretion in acromegalic but not in hyperprolactinaemic patients. 59
Totale 10.288
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.713
article - articoli 0
book - libri 0
conference - conferenze 1.849
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.562
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.327 0 0 0 0 169 385 177 103 196 124 122 51
2020/20211.612 128 58 132 72 191 66 173 117 179 169 122 205
2021/20221.706 50 87 90 71 117 90 118 90 70 116 379 428
2022/20232.726 310 209 41 290 237 685 193 146 308 73 164 70
2023/20241.121 164 199 52 68 59 103 43 77 21 63 98 174
2024/20251.370 24 262 84 349 651 0 0 0 0 0 0 0
Totale 14.108